Результаты поиска

Bone sialoprotein: a multifunctional regulator of bone remodelling and tumour progression.

Bone sialoprotein (BSP) is a major non-collagenous protein of the bone extracellular matrix and an important regulator of bone formation and resorption. BSP is produced by bone cells and chondrocytes and present in the bone matrix, cells, dentin and cartilage. However, its aberrant expression in primary tumour tissues and the sera of cancer patients with metastases implicates BSP in tumour biology and progression. The Arg-Gly-Asp (RGD) motif of BSP may be crucial not only for the attachment of metastasising cells to the bone surface but also for tumour growth, survival and activity. This revie

Совпадение в полном тексте источника
… The rat heparin-binding domain (FHRRIKA) synergises with RGD to promote rat osteoblast-like cell adhesion (FHRRIKA:RGD ratios 75:25, 25:75, 50:50, 4 h), but is insufficient to induce vinculin contact formation and actin cytoskeletal reorganisation alone. 28 Rat BSP (50 μg/mL, 2 h) binding to COL1 does … BSP binding activates RGD- and integrin-dependent signalling pathways, inducing focal adhesion complex formation involving vinculin and actin. 38 In MDA-MB-231, Hs578t and PC-3 cells, RGD-mediated binding stimulates focal adhesion kinase (FAK) and ERK phosphorylation. 38 Cell-BSP interactions, potentially …

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets.

Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and elucidating its molecular crosstalk with tumors is crucial for developing effective clinical therapies. Internal drivers of inflammation-tumor transformation include genomic disorder, epigenetic memory, mitochondrial stress, and metabolic reprogramming, which synergistically initiate carcinogenesis. External factors amplifying tumor progression cover immune dysfunction, stromal fibrosis, microbial dysbiosis, vascular neoplasia, and neurotoxicity, collectively accelerating tumor

Совпадение в полном тексте источника
… This bacterium not only inhibits the function of immune cells such as B cells and DC cells to reduce IgA + B cell homing but also induces vinculin acetylation by secreting acetic acid, disrupting intestinal barrier integrity. …

Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis.

The lungs represent the most common site of metastasis for osteosarcoma (OS). Despite our advances in developing targeted therapies for treating solid malignancies, broad acting chemotherapies remain the first line treatment for OS. In assaying the efficacy of approved therapeutics for non-OS malignancies, we previously identified the histone deacetylase 1 and 2 (HDAC1 and 2) inhibitor, romidepsin, as effective for the treatment of established lung metastatic OS. Yet, romidepsin has noted toxicities in humans and so here we aimed to define the primary mechanisms through which HDAC1/2 mediate O

Совпадение в полном тексте источника
… Actin and Vinculin were used as internal control to normalize the proteins across samples. For immunoblot in Fig. 6C , cells were serum starved for 24h, followed by addition of DMEM media with 10% serum for 5 min, 15 min and 1-h timepoints. …

Emergence of Cancer-Associated Fibroblasts as an Indispensable Cellular Player in Bone Metastasis Process.

Bone metastasis is frequently complicated in patients with advanced solid cancers such as breast, prostate and lung cancers, and impairs patients' quality of life and prognosis. At the first step of bone metastasis, cancer cells adhere to the endothelium in bone marrow and survive in a dormant state by utilizing hematopoietic niches present therein. Once a dormant stage is disturbed, cancer cells grow through the interaction with various bone marrow resident cells, particularly osteoclasts and osteoblasts. Consequently, osteoclast activation is a hallmark of bone metastasis. As a consequence,

Совпадение в полном тексте источника
… When subjected to force, this adhesion triggered β-catenin recruitment and adhesion reinforcement depending on α-catenin/vinculin interaction, leading to directional cancer cell migration and invasion. …

Osteocytes: New Kids on the Block for Cancer in Bone Therapy.

The tumor microenvironment plays a central role in the onset and progression of cancer in the bone. Cancer cells, either from tumors originating in the bone or from metastatic cancer cells from other body systems, are located in specialized niches where they interact with different cells of the bone marrow. These interactions transform the bone into an ideal niche for cancer cell migration, proliferation, and survival and cause an imbalance in bone homeostasis that severely affects the integrity of the skeleton. During the last decade, preclinical studies have identified new cellular mechanism

Совпадение в полном тексте источника
… Vinculin Force Sensor Detects Tumor-Osteocyte Interactions. Sci. Rep. 2019;9:5615. doi: 10.1038/s41598-019-42132-x. 38. Dwivedi A., Kiely P.A., Hoey D.A. Mechanically stimulated osteocytes promote the proliferation and migration of breast cancer cells via a potential CXCL1/2 mechanism. Biochem. …

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer.

One of the most common malignant tumors worldwide is lung cancer, and it is associated with the highest death rate among all cancers. Traditional treatment options for lung cancer include radiation, chemotherapy, targeted therapy, and surgical resection. However, the survival rate is low, and the outlook is still dreadfully dire. The pursuit of a paradigm change in treatment approaches is, therefore, imperative. Tyrosine kinases (TKs), a subclass of protein kinases, regulate vital cellular function by phosphorylating tyrosine residues in proteins. Mutations, overexpression, and autocrine parac

Совпадение в полном тексте источника
… . | [ 108 ] NSCLC | Treatment with EGCG decreases cell migration and alters the expression of vinculin and meta-vinculin. | [ 109 ] NSCLC | Combining EGCG derivatives with cisplatin inhibits the EGFR signaling pathway and reduces p-EGFR, p-AKT, and p-ERK expression both in vitro and in vivo. | [ 110 …

Bone targeted nano-drug and nano-delivery.

There are currently no targeted delivery systems to satisfactorily treat bone-related disorders. Many clinical drugs consisting of small organic molecules have a short circulation half-life and do not effectively reach the diseased tissue site. This coupled with repeatedly high dose usage that leads to severe side effects. With the advance in nanotechnology, drugs contained within a nano-delivery device or drugs aggregated into nanoparticles (nano-drugs) have shown promises in targeted drug delivery. The ability to design nanoparticles to target bone has attracted many researchers to develop n

Совпадение в полном тексте источника
… More bone was formed in nwCaP and wCaP. 90 c – f The calcium scaffold with different material surface curvature (G0, G2, G4 and G6) modulated osteoclacin (OCN) expression, more vinculin around nucleus and cell contractility. 97 g , h The SO 3 H - coated polyetheretherketon (PEEK) affected osteogenesis …

Резюме 18th Неевромускульная научно-исследовательская конференция Соединенного Королевства 15th и 16th апрель 2025.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Cardiomyopathy: pathogenesis and therapeutic interventions.

Cardiomyopathy is a group of disease characterized by structural and functional damage to the myocardium. The etiologies of cardiomyopathies are diverse, spanning from genetic mutations impacting fundamental myocardial functions to systemic disorders that result in widespread cardiac damage. Many specific gene mutations cause primary cardiomyopathy. Environmental factors and metabolic disorders may also lead to the occurrence of cardiomyopathy. This review provides an in-depth analysis of the current understanding of the pathogenesis of various cardiomyopathies, highlighting the molecular and

Совпадение в полном тексте источника
… Rare MYOZ2 9 | 4q26‐q27 | Myozenin 2 | Rare Z‐Disc HCM CSRP3 12 | 11p15.1 | Muscle LIM protein | Rare TCAP 12 | 17q12‐q21.1 | Telethonin | Rare LDB3 12 | 10q22.2‐q23.3 | LIM binding domain 3 | Rare ACTN1 12 | 14q24.1 | α‐Actinin 1 | Rare ACTN2 12 | 1q42‐q43 | α‐Actinin 2 | Rare VCL 12 | 10q22.1‐q23 | Vinculin …

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote tumor growth and therapeutic resistance. Elucidating the intricate interactions between cancer cells and the TME is crucial in understanding cancer progression and therapeutic challenges. A critical process induced by TME signaling is the epithelial-mesenchymal transition (EMT), wherein epithelial cells acquire mesenchymal traits, which enhance their motility and inva

ISEV2018 абстрактная книга

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Неделя ГЭЭ 2018 Презентации на плакате

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме: 32 Второй Конгресс ЭСП и Международный конгресс XXXIII МПД.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Results: The expression of F-actin paxillin, vinculin, HIF-1α, VEGF and eNOS in EC increased with increasing degree of C4d expression, PTC destruction, interstitial inflammation, glomerulitis and PTC-itis in glomeruli and PTCs (p<0.001). … The risk of the development of TG, IF, proteinuria, and graft loss found higher in recipients with a high degree of F-actin, paxillin, vinculin, HIF-1α, VEGF and eNOS expression (p<0.001). …

Абстрактный сборник ISEV2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме книги: ISEV2017.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ISEV2019 Abstract Book

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Esid 2014 oral presentations.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 28th Европейский конгресс педиатрической ремуматологии (ПСР) 2022) Прага, Чешская Республика. 20-23 сентябрь 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts of the 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, Texas, USA.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ISEV2025 Резюме книги.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.